Overactive Bladder Clinical Trials 2023

What are the top hospitals conducting overactive bladder research?

When it comes to finding innovative solutions for overactive bladder, several hospitals are leading the way in clinical trials. In Bethesda, Maryland, Walter Reed National Military Medical Center has been at the forefront of research with four ongoing trials and a total of five conducted studies dedicated to overactive bladder. Their first recorded trial in this field dates back to 2013. Meanwhile, UC Davis Health in Sacramento is making strides as well, currently running two active clinical trials for overactive bladder and contributing to the understanding of this condition through their earliest trial recorded just last year in 2021.

The University of Southern California (USC) located in Los Angeles is also actively involved in advancing knowledge about overactive bladder, conducting two ongoing trials while having accomplished four previous studies since recording their inaugural trial back in 2013. On the East Coast, Bay State Clinical Trials takes part by running one active trial for overactive bladder and contributing insights from nine completed studies dating back to their pioneering investigation on such cases starting all the way back until 2011.

Lastly but no less significant is Duke University Hospital situated within Durham where they have started exploring possibilities with regard to treatment options available along lines related with symptoms experienced due to OAB just recently; meaning that there exists only one current active test being carried out under its supervision throughout entire nation; thus far marking itself as sole entity progressing further even though scope may appear more limited compared alongside other aforementioned competitors who had progressed much prior.

These top hospitals dedicatedly working towards bettering outcomes for those affected by overactive bladder demonstrate a commitment to improving patients' quality of life. Each clinical trial serves as an opportunity to uncover new treatment approaches or interventions that address the challenges faced by individuals living with this condition. The collective efforts and breakthroughs achieved by these institutions pave the way for future advancements that hold promise for countless individuals seeking relief from overactive bladder symptoms

Which are the best cities for overactive bladder clinical trials?

When it comes to overactive bladder clinical trials, several cities are at the forefront of research and development. Los Angeles, California leads the way with 5 active trials investigating treatments such as INTIBIA Therapeutic, SUFU Clinical Care Pathway for Overactive Bladder, and StimRouter Treatment. Bethesda, Maryland follows closely behind with 4 ongoing studies focused on interventions like Xeomin and Mirabegron. Cleveland, Ohio also shows promise with 3 active trials exploring options such as Intravesical Botox injection and StimRouter Treatment. These cities offer individuals dealing with overactive bladder access to cutting-edge clinical trials that may lead to improved management of this condition.

Which are the top treatments for overactive bladder being explored in clinical trials?

Exciting developments are underway in the realm of overactive bladder treatments, with two standout contenders taking center stage in current clinical trials. First up is V117957, a promising treatment currently being explored in one active trial. With its recent listing in 2022, it shows great potential for addressing this condition. Another noteworthy contender is Pelvic Floor Muscle Training, also engaged in one ongoing trial and first listed just last year in 2023. These innovative approaches hold promise for improving the lives of individuals struggling with overactive bladder symptoms and offer hope for enhanced quality of life moving forward.

What are the most recent clinical trials for overactive bladder?

Exciting advancements are being made in the field of overactive bladder treatment, with recent clinical trials offering potential solutions for patients. One such trial focuses on intra-detrusor OnabotulinumtoxinA injection, which has entered Phase 2 and Phase 3 testing stages as a promising option for managing overactive bladder symptoms. Another study investigates the efficacy of Xeomin, currently in Phase 2 development, as a potential treatment. Additionally, Mirabegron 50 MG (Myrbetriq) is undergoing Phase 4 evaluation to assess its effectiveness and safety profile for patients with overactive bladder. V117957 is also being explored in an early-stage trial (Phase 1), while a separate research effort examines the benefits of a treatment group specifically designed to address overactive bladder concerns (Phase 4). With these diverse investigations underway, hope shines bright for improved management strategies against this condition.

What overactive bladder clinical trials were recently completed?

In the realm of overactive bladder research, several noteworthy clinical trials have recently concluded, bringing us closer to improved treatment options. In October 2021, the University of Alabama at Birmingham successfully completed a trial focused on Posterior Tibial Nerve Stimulation (PTNS). Bayer's investigation into BAY1817080 reached its completion in July 2020. Additionally, Urovant Sciences GmbH conducted two separate trials for Vibegron: one concluding in September 2019 and another in March 2019. Although slightly earlier, Vanderbilt University Medical Center wrapped up their trial examining the Injection of OnabotulinumtoxinA (BTX-A) therapy in July 2018. These significant advancements underscore ongoing efforts to tackle overactive bladder and offer hope to individuals grappling with this condition.